Archived explainer. For the current picture see today's SLS page.
SELLAS LIFE SCIENCES (SLS) is down -6.97% in the latest session. Our newswire has captured 2 stories on SLS across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
SLS stock is down 6.97% at $11.48 in today's session, marking a sharp reversal from its early morning open. The stock initially opened with a 2.0% gap up but quickly declined throughout the morning. The move reflects a shift in sentiment among traders, with bearish commentary from high-profile figures and a broader weakening in coverage tone contributing to the sell-off.
The stock opened at $12.59, a 2.0% gap up from the previous close of $12.34. However, it quickly lost ground, hitting an intraday low of $11.44 by 10:00 AM ET. The decline was driven by skepticism from market commentator Martin Shkreli, who questioned the timing of SELLAS Life Sciences' AML trial data and suggested it may not be released until the end of the year. This echoed concerns he has previously expressed about the company's timeline. Meanwhile, retail traders on platforms like Stocktwits have highlighted new AML survival data from MD Anderson, but the mixed reception of these developments appears to have contributed to the stock's downward momentum. The CEO's upcoming appearance on Fox has not yet provided clarity, and coverage from the last 36 hours includes two stories from one source, both highlighting uncertainty.
SLS has a market cap of $2.4 billion and remains unprofitable with a trailing 12-month EPS of -0.23. The stock has traded between $1.39 and $15.88 over the past 52 weeks. Today's volume of 1.6 million shares is 0.2 times the 3-month daily average, suggesting limited institutional activity. The stock has declined 1.1% over the last 8 sessions, from $12.78 to $12.64, and sentiment has deteriorated in the last 7 days to 51/100 from an average of 55/100. There were no unusual options activity, insider filings, or congressional trades reported.
The stock will need to navigate continued skepticism from market commentators and potential retail interest. Investors should monitor the CEO's Fox appearance for any new developments and watch for a potential earnings report if one is scheduled.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.
Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.
More on SLS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier SLS move explainers: 2026-07-27 · 2026-07-24 · 2026-07-22 · 2026-07-20 · 2026-07-17 · 2026-07-13